Zip, others, my memory is so cloudy about this and not to mention that I have tried to erase as much of the past wrt Amarin, that I may not be recollecting correctly. But here goes.
Was there not some talk here years ago (I think after the DuDisaster) about some process whereby Amarin would withdraw (not sure if that is the right word) V from the VHTG indication and have it strictly be a CVD med. I can't remember if those suggesting that thought that it would remove the Generics from the market? Possible? or complete nonsense?
I have to assume that if it was that easy that even the prior bumbling management would have done it.
As an aside, I have some shares in another stock where an investor wants to vote out 3 board members (including the CEO) at their upcoming AGM, and this Glass Lewis has been called in just like with Amarin to recommend that voters save management's bacon. Hope we get the same result.
News 
Market Data 
Discover 
